BIBLIOTHEQUE CENTRALE
Détail de l'auteur
Auteur Gary Walsh |
Documents disponibles écrits par cet auteur
Affiner la recherche Interroger des sources externes
Titre : Pharmaceutical Biotechnology : Concepts and Applications Type de document : texte imprimé Auteurs : Gary Walsh, Auteur Mention d'édition : 1er édition Editeur : England : John Wiley et Sons Ltd Année de publication : 2013 Importance : 480 pages Présentation : couv., ill., tab.,fig. Format : 19× 25cm ISBN/ISSN/EAN : 978-0-470-01245-1 Langues : Anglais (eng) Langues originales : Anglais (eng) Mots-clés : technology Pharmaceutical Biotechnology Index. décimale : 615 Pharlacikigue et thérapeutique Résumé : Pharmaceutical Biotechnology offers students taking Pharmacy and related Medical and Pharmaceutical courses a comprehensive introduction to the fast-moving area of biopharmaceuticals. With a particular focus on the subject taken from a pharmaceutical perspective, initial chapters offer a broad introduction to protein science and recombinant DNA technology- key areas that underpin the whole subject. Subsequent chapters focus upon the development, production and analysis of these substances. Finally the book moves on to explore the science, biotechnology and medical applications of specific biotech products categories. These include not only protein-based substances but also nucleic acid and cell-based products.
introduces essential principles underlining modern biotechnology- recombinant DNA technology and protein science
an invaluable introduction to this fast-moving subject aimed specifically at pharmacy and medical students
includes specific ‘product category chapters’ focusing on the pharmaceutical, medical and therapeutic properties of numerous biopharmaceutical products.
entire chapter devoted to the principles of genetic engineering and how these drugs are developed.
includes numerous relevant case studies to enhance student understanding
no prior knowledge of protein structure is assumedNote de contenu : TABLE OF CONTENTS
Preface.
Acronyms.
1 Pharmaceuticals, biologics and biopharmaceuticals.
1.1 Introduction to pharmaceutical products.
1.2 Biopharmaceuticals and pharmaceutical biotechnology.
1.3 History of the pharmaceutical industry.
1.4 The age of biopharmaceuticals.
1.5 Biopharmaceuticals: current status and future prospects.
2 Protein structure.
2.1 Introduction.
2.2 Overview of protein structure.
2.3 Higher level structure.
2.4 Protein stability and folding.
2.5 Protein post-translational modifi cation.
3 Gene manipulation and recombinant DNA technology.
3.1 Introduction.
3.2 Nucleic acids: function and structure.
3.3 Recombinant production of therapeutic proteins.
3.4 Classical gene cloning and identifi cation.
4 The drug development process.
4.1 Introduction.
4.2 Discovery of biopharmaceuticals.
4.3 The impact of genomics and related technologies upon drug discovery.
4.4 Gene chips.
4.5 Proteomics.
4.6 Structural genomics.
4.7 Pharmacogenetics.
4.8 Initial product characterization.
4.9 Patenting.
4.10 Delivery of biopharmaceuticals.
4.10.3 Nasal, transmucosal and transdermal delivery systems.
4.11 Preclinical studies.
4.12 Pharmacokinetics and pharmacodynamics.
4.13 Toxicity studies.
4.14 The role and remit of regulatory authorities.
4.15 Conclusion.
5 Sources and upstream processing.
5.1 Introduction.
5.2 Sources of biopharmaceuticals.
5.3 Upstream processing.
6 Downstream processing.
6.1 Introduction.
6.2 Initial product recovery.
6.3 Cell disruption.
6.4 Removal of nucleic acid.
6.5 Initial product concentration.
6.6 Chromatographic purifi cation.
6.7 High-performance liquid chromatography of proteins.
6.8 Purifi cation of recombinant proteins.
6.9 Final product formulation.
7 Product analysis.
7.1 Introduction.
7.2 Protein-based contaminants.
7.3 Removal of altered forms of the protein of interest from the product stream.
7.4 Detection of protein-based product impurities.
7.5 Immunological approaches to detection of contaminants.
7.6 Endotoxin and other pyrogenic contaminants.
8 The cytokines: The interferon family.
8.1 Cytokines.
8.1.1 Cytokine receptors.
8.1.2 Cytokines as biopharmaceuticals.
8.2 The interferons.
8.3 Interferon biotechnology.
8.4 Conclusion.
9 Cytokines: Interleukins and tumour necrosis factor.
9.1 Introduction.
9.2 Interleukin-2.
9.3 Interleukin-1.
9.4 Interleukin-11.
9.5 Tumour necrosis factors.
10 Growth factors.
10.1 Introduction.
10.2 Haematopoietic growth factors.
10.3 Growth factors and wound healing.
11 Therapeutic hormones.
11.1 Introduction.
11.2 Insulin.
11.3 Glucagon.
11.4 Human growth hormone.
11.5 The gonadotrophins.
11.6 Medical and veterinary applications of gonadotrophins.
11.7 Additional recombinant hormones now approved.
11.8 Conclusion.
12 Recombinant blood products and therapeutic enzymes.
12.1 Introduction.
12.2 Haemostasis.
12.3 Anticoagulants.
12.4 Thrombolytic agents.
12.5 Enzymes of therapeutic value.
13 Antibodies, vaccines and adjuvants.
13.1 Introduction.
13.2 Traditional polyclonal antibody preparations.
13.3 Monoclonal antibodies.
13.4 Vaccine technology.
13.5 Adjuvant technology.
14 Nucleic-acid- and cell-based therapeutics.
14.1 Introduction.
14.2 Gene therapy.
14.3 Vectors used in gene therapy.
14.4 Gene therapy and genetic disease.
14.5 Gene therapy and cancer.
14.6 Gene therapy and AIDS.
14.7 Antisense technology.
14.8 Oligonucleotide pharmacokinetics and delivery.
14.9 Aptamers.
14.10 Cell- and tissue-based therapies.
14.11 Conclusion.
Index.Pharmaceutical Biotechnology : Concepts and Applications [texte imprimé] / Gary Walsh, Auteur . - 1er édition . - [S.l.] : England : John Wiley et Sons Ltd, 2013 . - 480 pages : couv., ill., tab.,fig. ; 19× 25cm.
ISBN : 978-0-470-01245-1
Langues : Anglais (eng) Langues originales : Anglais (eng)
Mots-clés : technology Pharmaceutical Biotechnology Index. décimale : 615 Pharlacikigue et thérapeutique Résumé : Pharmaceutical Biotechnology offers students taking Pharmacy and related Medical and Pharmaceutical courses a comprehensive introduction to the fast-moving area of biopharmaceuticals. With a particular focus on the subject taken from a pharmaceutical perspective, initial chapters offer a broad introduction to protein science and recombinant DNA technology- key areas that underpin the whole subject. Subsequent chapters focus upon the development, production and analysis of these substances. Finally the book moves on to explore the science, biotechnology and medical applications of specific biotech products categories. These include not only protein-based substances but also nucleic acid and cell-based products.
introduces essential principles underlining modern biotechnology- recombinant DNA technology and protein science
an invaluable introduction to this fast-moving subject aimed specifically at pharmacy and medical students
includes specific ‘product category chapters’ focusing on the pharmaceutical, medical and therapeutic properties of numerous biopharmaceutical products.
entire chapter devoted to the principles of genetic engineering and how these drugs are developed.
includes numerous relevant case studies to enhance student understanding
no prior knowledge of protein structure is assumedNote de contenu : TABLE OF CONTENTS
Preface.
Acronyms.
1 Pharmaceuticals, biologics and biopharmaceuticals.
1.1 Introduction to pharmaceutical products.
1.2 Biopharmaceuticals and pharmaceutical biotechnology.
1.3 History of the pharmaceutical industry.
1.4 The age of biopharmaceuticals.
1.5 Biopharmaceuticals: current status and future prospects.
2 Protein structure.
2.1 Introduction.
2.2 Overview of protein structure.
2.3 Higher level structure.
2.4 Protein stability and folding.
2.5 Protein post-translational modifi cation.
3 Gene manipulation and recombinant DNA technology.
3.1 Introduction.
3.2 Nucleic acids: function and structure.
3.3 Recombinant production of therapeutic proteins.
3.4 Classical gene cloning and identifi cation.
4 The drug development process.
4.1 Introduction.
4.2 Discovery of biopharmaceuticals.
4.3 The impact of genomics and related technologies upon drug discovery.
4.4 Gene chips.
4.5 Proteomics.
4.6 Structural genomics.
4.7 Pharmacogenetics.
4.8 Initial product characterization.
4.9 Patenting.
4.10 Delivery of biopharmaceuticals.
4.10.3 Nasal, transmucosal and transdermal delivery systems.
4.11 Preclinical studies.
4.12 Pharmacokinetics and pharmacodynamics.
4.13 Toxicity studies.
4.14 The role and remit of regulatory authorities.
4.15 Conclusion.
5 Sources and upstream processing.
5.1 Introduction.
5.2 Sources of biopharmaceuticals.
5.3 Upstream processing.
6 Downstream processing.
6.1 Introduction.
6.2 Initial product recovery.
6.3 Cell disruption.
6.4 Removal of nucleic acid.
6.5 Initial product concentration.
6.6 Chromatographic purifi cation.
6.7 High-performance liquid chromatography of proteins.
6.8 Purifi cation of recombinant proteins.
6.9 Final product formulation.
7 Product analysis.
7.1 Introduction.
7.2 Protein-based contaminants.
7.3 Removal of altered forms of the protein of interest from the product stream.
7.4 Detection of protein-based product impurities.
7.5 Immunological approaches to detection of contaminants.
7.6 Endotoxin and other pyrogenic contaminants.
8 The cytokines: The interferon family.
8.1 Cytokines.
8.1.1 Cytokine receptors.
8.1.2 Cytokines as biopharmaceuticals.
8.2 The interferons.
8.3 Interferon biotechnology.
8.4 Conclusion.
9 Cytokines: Interleukins and tumour necrosis factor.
9.1 Introduction.
9.2 Interleukin-2.
9.3 Interleukin-1.
9.4 Interleukin-11.
9.5 Tumour necrosis factors.
10 Growth factors.
10.1 Introduction.
10.2 Haematopoietic growth factors.
10.3 Growth factors and wound healing.
11 Therapeutic hormones.
11.1 Introduction.
11.2 Insulin.
11.3 Glucagon.
11.4 Human growth hormone.
11.5 The gonadotrophins.
11.6 Medical and veterinary applications of gonadotrophins.
11.7 Additional recombinant hormones now approved.
11.8 Conclusion.
12 Recombinant blood products and therapeutic enzymes.
12.1 Introduction.
12.2 Haemostasis.
12.3 Anticoagulants.
12.4 Thrombolytic agents.
12.5 Enzymes of therapeutic value.
13 Antibodies, vaccines and adjuvants.
13.1 Introduction.
13.2 Traditional polyclonal antibody preparations.
13.3 Monoclonal antibodies.
13.4 Vaccine technology.
13.5 Adjuvant technology.
14 Nucleic-acid- and cell-based therapeutics.
14.1 Introduction.
14.2 Gene therapy.
14.3 Vectors used in gene therapy.
14.4 Gene therapy and genetic disease.
14.5 Gene therapy and cancer.
14.6 Gene therapy and AIDS.
14.7 Antisense technology.
14.8 Oligonucleotide pharmacokinetics and delivery.
14.9 Aptamers.
14.10 Cell- and tissue-based therapies.
14.11 Conclusion.
Index.Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité 11/179486 L/615.013 Livre Bibliothèque Centrale indéterminé Exclu du prêt
Titre : Post-translational Modification of Protein Biopharmaceuticals Type de document : texte imprimé Auteurs : Gary Walsh, Auteur Editeur : Wiley-Blackwell Année de publication : 2009 Importance : 370 P. Présentation : couv., ill., tab.,fig. Format : 17 x 24 cm. ISBN/ISSN/EAN : 978-3-527-32074-5 Langues : Anglais (eng) Langues originales : Anglais (eng) Index. décimale : 615 Pharlacikigue et thérapeutique Résumé : From the leading author in the field, known around the world for his work and his authoritative publications, the contents of this book have been selected so as to reflect their relative importance for biopharmaceuticals. As a result, around half of the book is devoted to protein glycosylation, while the remainder is made up of other modifications, such as carboxylation, hydroxylation, sulfation, amidation and proteolytic processing. A final section addresses the latest trend of engineering the modification pattern to improve a given biopharmceutical, presenting several recent case studies of successful posttranslational engineering.
This first authoritative overview of the topic is an indispensable guide for drug developers and drug manufacturers with an interest in protein pharmaceuticals.Note de contenu : TABLE OF CONTENTS
1 Post translational modifications in the context of therapeutic proteins; an introductory overview (Walsh)
2 Protein glycosylation; the basic science (Brookes)
3 Mammalian cell lines and glycosylation; a case study (Butler)
4 Antibody glycosylation (Jefferis)
5 Gonadotropins and the importance of glycosylation (Ulloa-Aguirre)
6 Yeast glycosylation and engineering in the context of therapeutic proteins (Sethuraman)
7 Insect cell glycosylation patterns in the context of biopharmaceuticals (Jarvis)
8 Getting Bacteria to glycosylate (Kowarik, Feldman)
9 Glycoengineering of Erythropoietin (Elliott)
10 Glycoengineering: Cerezyme as a case study (Van Patten, Edmunds)
11 Carboxylation and Hydroxylation (Brown, Stenberg)
12 C-Terminal a-Amidation (Mehta, Carpenter)
13 Disulfide bond formation (Collett)
14 Engineering in a PTM: PEGylation (Bonora, Veronese)
Post-translational Modification of Protein Biopharmaceuticals [texte imprimé] / Gary Walsh, Auteur . - England : Wiley-Blackwell, 2009 . - 370 P. : couv., ill., tab.,fig. ; 17 x 24 cm.
ISBN : 978-3-527-32074-5
Langues : Anglais (eng) Langues originales : Anglais (eng)
Index. décimale : 615 Pharlacikigue et thérapeutique Résumé : From the leading author in the field, known around the world for his work and his authoritative publications, the contents of this book have been selected so as to reflect their relative importance for biopharmaceuticals. As a result, around half of the book is devoted to protein glycosylation, while the remainder is made up of other modifications, such as carboxylation, hydroxylation, sulfation, amidation and proteolytic processing. A final section addresses the latest trend of engineering the modification pattern to improve a given biopharmceutical, presenting several recent case studies of successful posttranslational engineering.
This first authoritative overview of the topic is an indispensable guide for drug developers and drug manufacturers with an interest in protein pharmaceuticals.Note de contenu : TABLE OF CONTENTS
1 Post translational modifications in the context of therapeutic proteins; an introductory overview (Walsh)
2 Protein glycosylation; the basic science (Brookes)
3 Mammalian cell lines and glycosylation; a case study (Butler)
4 Antibody glycosylation (Jefferis)
5 Gonadotropins and the importance of glycosylation (Ulloa-Aguirre)
6 Yeast glycosylation and engineering in the context of therapeutic proteins (Sethuraman)
7 Insect cell glycosylation patterns in the context of biopharmaceuticals (Jarvis)
8 Getting Bacteria to glycosylate (Kowarik, Feldman)
9 Glycoengineering of Erythropoietin (Elliott)
10 Glycoengineering: Cerezyme as a case study (Van Patten, Edmunds)
11 Carboxylation and Hydroxylation (Brown, Stenberg)
12 C-Terminal a-Amidation (Mehta, Carpenter)
13 Disulfide bond formation (Collett)
14 Engineering in a PTM: PEGylation (Bonora, Veronese)
Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité 11/186035 L/615.015 Livre Bibliothèque Centrale indéterminé Exclu du prêt
